1 / 7

Update on the Safety of Erythropoietin Products in Patients With Cancer

Update on the Safety of Erythropoietin Products in Patients With Cancer. May 4, 2004 Robert DeLap, MD, PhD Vice President, Global Regulatory Affairs Johnson & Johnson Pharmaceutical Research & Development. Background Chemotherapy-associated Anemia. Chemotherapy frequently causes anemia

vasilis
Download Presentation

Update on the Safety of Erythropoietin Products in Patients With Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on the Safety of Erythropoietin Products in Patients With Cancer May 4, 2004 Robert DeLap, MD, PhD Vice President, Global Regulatory Affairs Johnson & JohnsonPharmaceutical Research & Development

  2. BackgroundChemotherapy-associated Anemia • Chemotherapy frequently causes anemia • Debilitating symptoms, may require transfusion • Erythropoietin products valuable alternative to transfusion • Patient benefits • Conservation of blood supply • Demonstrated safety profile in multiple indications • Extensive clinical experience • Epoetin alfa—widely studied • Over 2 million patients with cancer treated with PROCRIT® and EPREX®

  3. Erythropoietin Products for Chemotherapy-associated Anemia

  4. Definitions • Supportive anemia care: studies evaluating the established indication, treatment of anemia • Goal is to obtain sufficient rise in hemoglobin to reduce need for transfusion • Beyond correction of anemia: investigational studies treating to higher hemoglobin levels • Includes most of the recent studies evaluating effects of erythropoietic agents on cancer treatment outcomes (response, progression, survival)

  5. Safety Data to Be Presented • In supportive anemia care, data and extensive clinical experience support the favorable benefit/risk profile of epoetin alfa • In some investigational studies of erythropoietin products used beyond correction of anemia, evidence of increased risk has been observed • Additional data are being collected, and further research is under consideration

  6. Today’s Agenda Evaluation of Studies Dr. Peter Bowers • Supportive Anemia Care • Beyond Correction of Anemia Future Clinical Data Dr. Martine George Conclusions Dr. Martine George

  7. Advisors

More Related